the o2h human health EIS knowledge-intensive fund

Over the last 15 years the o2h group have been at the forefront of life sciences building a track record of nurturing, supporting and investing in emerging companies, covering biotech, small molecule, biologics, digital and digital health.
Whilst growing their own drug discovery services business since 2005, founders Sunil and Prashant cultivated the skills to spot scientific talent, and cross-reference the quality of the science, early on, well before larger competitors got a look-in. This together with our privileged access to deal flow through carefully cultivated channels and excellent market knowledge puts o2h at the forefront of investing in cutting edge emerging life science.
o2h Ventures is an exciting position for nurturing early stage life science assets through seed investment, working alongside and investing in Knowledge-Intensive Companies that can look to generate returns (financial, social and ethical) for investors as part of the post-seed and early finance cycle.
The o2h human health EIS KI fund is intended for investors who want to achieve capital growth (rather than income) by investing in a Portfolio of unquoted and/or AIM-listed companies, that have the potential to increase in value significantly. All the Investments we ordinarily make will be in Knowledge-Intensive companies that are EIS qualifying. When you invest in the Fund, you appoint o2h Ventures to invest your subscriptions in companies and manage those Investments on your behalf on a discretionary basis.
We endeavour to take an active role in managing these Investments, as at this early stage these companies often require more than funds to succeed. We will seek to embed these companies into an o2h-curated innovation ecosystem where possible to allow these potential companies to create value and achieve the best possible exits for investors.